Dr. Fan is the founder of Legend Biotech and currently serves the company as the Chief Scientific Officer. Dr. Fan received his medical degree at Xi’an Jiaotong University in 1993 and worked as surgical resident in kidney Transplantation Centre of the university before he pursued and obtained his Ph.D. in applied immunology at Hiroshima University, Japan. He completed his postdoctoral training at the Hospital for Sick Children, University of Toronto, Canada where he became recognized as an expert in the field of the mechanism of human B cell tolerance. Dr. Fan has been published in numerous peer-reviewed academic journals, including a major revision in the clinical guidelines of pediatric organ transplantation published in Nature Medicine. Before Dr. Fan elucidated the mechanism of neonatal B cell tolerance, organ transplantation has to be conducted between ABO blood type matched donor and recipient. Dr. Fan‘s scientific achievement pave the way that small children can be safely transplanted with ABO mismatched organ, thus saved many life of infant patients. Thus, Dr. Fan was awarded a “New Key Opinion Leader” award by The Transplantation Society in 2006. Dr. Fan founded Legend Biotech in 2014 and built an elite R&D team exploring innovative precision cell therapy. In just 4 years, the company grew from a start-up company to a global leader in cancer immunotherapy. Since 2017, Legend Biotech entered a global partnership with Janssen to co-develop a BCMA targeting CAR-T product Dr. Fan invented in US, EU, China and Japan markets. The promising data obtained in early phase of study strongly support the product to bear potential of a blockbuster.